伊布替尼单药治疗难治复发性B细胞淋巴瘤3例并文献复习

Single-agent Ibrutinib in the treatment of relapsed and refractory B cell lymphoma:three cases report and literature review

Bruton酪氨酸激酶(Bruton tyrosine kinase,BTK)是B细胞受体(B cell receptor,BCR)信号通路的重要中介分子,在B细胞淋巴瘤的形成中发挥重要作用。伊布替尼(Ibrutinib)是口服不可逆BTK抑制剂,可有效抑制B细胞增殖并诱导其凋亡。

Bruton’s tyrosine kinase(BTK),an important mediator of the BCR signal pathway,plays an important role in the formation of B-cell lymphoma.Ibrutinib is an oral active BTK inhibitor that effectively inhibits the malignant proliferation and induces apoptosis of B cells.As a single agent,it has shown extremely promising activity in relapsed and refractory B-cell lymphoma patients with well tolerability and acceptable toxicities.In our department,3 patients with relapsed and refractory B-cell lymphoma received single-agent Ibrutinib achieved remission in short time.